Biomarker-driven protocol model broadens lung cancer trial access for some underrepresented groups
As compared to conventional, stand-alone clinical trials in advanced non-small cell lung cancer (NSCLC), the biomarker-driven Lung Cancer Master Protocol (Lung-MAP) has enrolled higher percentages of patients who are older, ...
Sep 7, 2023
0
1